Mar 20, 2006 · Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies.

5 days ago · In the latest move to cement its “immunology powerhouse” status, Sanofi is handing over $600 million upfront for Dren Bio’s clinical-stage bispecific antibody, with more than $1 billion in ...

5 days ago · Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune ...

4 days ago · Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific …

5 days ago · Sanofi buys a drug from Dren Bio to claim a stake in the emerging field of deep B-cell depletion for autoimmune diseases.

5 days ago · Sanofi has reached an agreement with Dren Bio to acquire DR-020, a CD20-directed bispecific antibody currently in early clinical trials for refractory B-cell-mediated autoimmune diseases, in a deal that could be valued at up to $1.9 billion.

5 days ago · In the latest investment in the immunology space, Sanofi has agreed to a $600 million upfront payment to buy Dren Bio’s investigational bispecific antibody DR-0201 in a deal announced Thursday. The asset is a targeted cell engager that binds to the CD20 protein on B cells, tagging them for destruction.

Paris, March 20, 2025. Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies.

5 days ago · Sanofi is continuing its immunology pipeline push with an agreement to acquire Dren Bio’s bispecific antibody DR-0201 in a deal whose value could rise to $1.9bn. The deal for the clinical asset will be made through Sanofi’s acquisition of Dren Bio affiliate Dren-0201. The French company will pay $600m upfront, with milestone payments of $1.3bn.

5 days ago · Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs aiming to “reset” the immune …